Martin Hegen
Pfizer (United States)(US)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, Rheumatoid Arthritis Research and Therapies, Monoclonal and Polyclonal Antibodies Research, Peptidase Inhibition and Analysis, T-cell and B-cell Immunology
Most-Cited Works
- → Parsing the Interferon Transcriptional Network and Its Disease Associations(2016)341 cited
- → Utility of animal models for identification of potential therapeutics for rheumatoid arthritis(2007)295 cited
- → Blockade of the interleukin‐21/interleukin‐21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis(2007)271 cited
- → Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response(1996)213 cited
- → Animal models for arthritis: innovative tools for prevention and treatment(2011)199 cited
- → Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition(2016)189 cited
- Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.(2003)
- → The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity.(1990)172 cited
- → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
- → Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases(2018)163 cited